These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31028057)

  • 1. Indinavir Increases Midazolam
    Tian DD; Leonowens C; Cox EJ; González-Pérez V; Frederick KS; Scarlett YV; Fisher MB; Paine MF
    Drug Metab Dispos; 2019 Jul; 47(7):724-731. PubMed ID: 31028057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans.
    Klieber S; Hugla S; Ngo R; Arabeyre-Fabre C; Meunier V; Sadoun F; Fedeli O; Rival M; Bourrie M; Guillou F; Maurel P; Fabre G
    Drug Metab Dispos; 2008 May; 36(5):851-62. PubMed ID: 18256203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
    Mao J; Johnson TR; Shen Z; Yamazaki S
    Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7.
    Seo KA; Bae SK; Choi YK; Choi CS; Liu KH; Shin JG
    Drug Metab Dispos; 2010 Nov; 38(11):2007-13. PubMed ID: 20713656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations.
    Nguyen JT; Tian DD; Tanna RS; Arian CM; Calamia JC; Rettie AE; Thummel KE; Paine MF
    J Pharmacol Exp Ther; 2023 Dec; 387(3):252-264. PubMed ID: 37541764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.
    Robertson SM; Formentini E; Alfaro RM; Falloon J; Penzak SR
    Pharmacotherapy; 2006 Aug; 26(8):1051-9. PubMed ID: 16863481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
    Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
    Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
    Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
    J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of 1'-hydroxymidazolam glucuronidation in human liver microsomes.
    Zhu B; Bush D; Doss GA; Vincent S; Franklin RB; Xu S
    Drug Metab Dispos; 2008 Feb; 36(2):331-8. PubMed ID: 17998299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically Based Pharmacokinetic Modeling to Predict the Impact of Liver Cirrhosis on Glucuronidation via UGT1A4 and UGT2B7/2B4-A Case Study with Midazolam.
    Ozbey AC; Keemink J; Wagner B; Pugliano A; Krähenbühl S; Annaert P; Fowler S; Parrott N; Umehara K
    Drug Metab Dispos; 2024 Jun; 52(7):614-625. PubMed ID: 38653501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
    Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.
    Namba H; Nishimura Y; Kurata N; Iwase M; Hirai T; Kiuchi Y
    Biol Pharm Bull; 2017; 40(9):1361-1365. PubMed ID: 28867721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).
    Kharasch ED; Bedynek PS; Hoffer C; Walker A; Whittington D
    Anesthesiology; 2012 Feb; 116(2):432-47. PubMed ID: 22273859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species differences and substrate specificity of CYP3A heteroactivation by efavirenz.
    Kosugi Y; Takahashi J
    Xenobiotica; 2015 Apr; 45(4):345-52. PubMed ID: 25387130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of Action of Panaxytriol on Midazolam 1'-Hydroxylation and 4-Hydroxylation Mediated by CYP3A in Liver Microsomes and Rat Primary Hepatocytes.
    He F; Zhang W; Zeng C; Xia C; Xiong Y; Zhang H; Huang S; Liu M
    Biol Pharm Bull; 2015; 38(10):1470-7. PubMed ID: 26424012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
    Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
    Ito K; Ogihara K; Kanamitsu S; Itoh T
    Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
    Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.
    Zhang D; Chando TJ; Everett DW; Patten CJ; Dehal SS; Humphreys WG
    Drug Metab Dispos; 2005 Nov; 33(11):1729-39. PubMed ID: 16118329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
    Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
    Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.